Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516862 | 0.96 | ALDH1A1 (0.71) | ALDH1A1TDP1HSD17B10KDM4ERAB9A | |
| SCHEMBL16784218 | 0.94 | ALDH1A1 (0.65) | ALDH1A1TDP1HSD17B10KDM4ERAB9A | |
| SCHEMBL16472567 | 0.94 | ALDH1A1 (0.69) | ALDH1A1TDP1HSD17B10KDM4ERAB9A | |
| SCHEMBL15853573 | 0.94 | ALDH1A1 (0.69) | ALDH1A1TDP1HSD17B10KDM4ERAB9A | |
| SCHEMBL16784223 | 0.93 | ALDH1A1 (0.62) | ALDH1A1TDP1HSD17B10KDM4ERAB9A | |
| SCHEMBL30576999 | 0.92 | ALDH1A1 (0.77) | ALDH1A1TDP1HSD17B10KDM4ERAB9A | |
| SCHEMBL210494 | 0.92 | ALDH1A1 (0.77) | ALDH1A1TDP1HSD17B10KDM4ERAB9A | |
| Ammonia Solution, Strong SCHEMBL28566017 | 0.90 | ALDH1A1 (0.74) | ALDH1A1TDP1HSD17B10KDM4ERAB9A | |
| SCHEMBL16559899 | 0.89 | ALDH1A1 (0.62) | ALDH1A1TDP1HSD17B10KDM4ERAB9A | |
| SCHEMBL16784219 | 0.89 | ALDH1A1 (0.62) | ALDH1A1TDP1HSD17B10KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022152705-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-07-21 | — | — | WO | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200278355-A1 | CONJUGATED PROTEINS AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200278355-A1 | CONJUGATED PROTEINS AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2020-09-03 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
| EP-1551829-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050136444-A1 | Treating neuropathic pain with neuropeptide FF receptor 2 agonists | ACADIA PHARMACEUTICALS INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2005031000-A2 | TREATING NEUROPATHIC PAIN WITH NEUROPEPTIDE FF RECEPTOR 2 AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040229868-A1 | Heterocyclic compounds, methods for the preparation thereof, and uses thereof | MEMORY PHARMACEUTICALS CORP. | 2004-11-18 | — | — | US | disclosed |
| WO-2004035569-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-04-29 | — | — | WO | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| EP-1358169-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057261-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-25 | — | — | WO | disclosed |
| US-4177272-A | HYPOTENSIVE, VASODILATION, PARKINSON'S DISEASE | SCIENCE UNION ET CIE (FR) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229868-A1 | Heterocyclic compounds, methods for the preparation thereof, and uses thereof | CHRNA1, CHRNA4, CHRNA3 | ALDH1A1 370/4885TDP1 2860/4885HSD17B10 1598/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | ALDH1A1 2424/4885TDP1 688/4885HSD17B10 4154/4885 |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | ALDH1A1 1439/4885TDP1 1796/4885HSD17B10 867/4885 |
| US-20200278355-A1 | CONJUGATED PROTEINS AND USES THEREOF | KEAP1, GSTK1, GSTM2 | ALDH1A1 1225/4885TDP1 3019/4885HSD17B10 1912/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | ALDH1A1 3670/4885TDP1 1447/4885HSD17B10 2409/4885 |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | ALDH1A1 2434/4885TDP1 4486/4885HSD17B10 774/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | ALDH1A1 1723/4885TDP1 2688/4885HSD17B10 3259/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | ALDH1A1 3670/4885TDP1 1447/4885HSD17B10 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.